搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Xanthomonas oryzae pv. oryzae tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG (mnmG), partial CSB-YP652383XAAB
CSB-EP652383XAAB
CSB-BP652383XAAB
CSB-MP652383XAAB
CSB-EP652383XAAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas oryzae pv. oryzae DNA replication and repair protein recF (recF) CSB-YP652384XAAB
CSB-EP652384XAAB
CSB-BP652384XAAB
CSB-MP652384XAAB
CSB-EP652384XAAB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Autoinducer 2 import system permease protein lsrD (lsrD), partial CSB-YP652385PCAD
CSB-EP652385PCAD
CSB-BP652385PCAD
CSB-MP652385PCAD
CSB-EP652385PCAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Zaire ebolavirus Matrix protein VP40 (VP40) CSB-YP652386ZAS
CSB-EP652386ZAS
CSB-BP652386ZAS
CSB-MP652386ZAS
CSB-EP652386ZAS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bubalus carabanensis Interleukin-12 subunit beta (IL12B) CSB-YP652387BAAW
CSB-EP652387BAAW
CSB-BP652387BAAW
CSB-MP652387BAAW
CSB-EP652387BAAW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Macaca fascicularis Protein sprouty homolog 2 (SPRY2) CSB-YP652388MOV
CSB-EP652388MOV
CSB-BP652388MOV
CSB-MP652388MOV
CSB-EP652388MOV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Macaca fascicularis RNA-binding protein Nova-1 (NOVA1) CSB-YP652389MOV
CSB-EP652389MOV
CSB-BP652389MOV
CSB-MP652389MOV
CSB-EP652389MOV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza A virus Matrix protein 1 (M) CSB-YP652390IAAO
CSB-EP652390IAAO
CSB-BP652390IAAO
CSB-MP652390IAAO
CSB-EP652390IAAO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Influenza A virus Matrix protein 2 (M), partial CSB-YP652391IAAI1
CSB-EP652391IAAI1
CSB-BP652391IAAI1
CSB-MP652391IAAI1
CSB-EP652391IAAI1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glycine max Protein ycf2 (ycf2-A), partial CSB-YP652392GGV
CSB-EP652392GGV
CSB-BP652392GGV
CSB-MP652392GGV
CSB-EP652392GGV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glycine max NAD (P)H-quinone oxidoreductase subunit I, chloroplastic (ndhI) CSB-YP652393GGV
CSB-EP652393GGV
CSB-BP652393GGV
CSB-MP652393GGV
CSB-EP652393GGV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glycine max 30S ribosomal protein S8, chloroplastic (rps8) CSB-YP652394GGV
CSB-EP652394GGV
CSB-BP652394GGV
CSB-MP652394GGV
CSB-EP652394GGV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glycine max Photosystem II CP47 chlorophyll apoprotein (psbB), partial CSB-YP652395GGV1
CSB-EP652395GGV1
CSB-BP652395GGV1
CSB-MP652395GGV1
CSB-EP652395GGV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glycine max Cytochrome b559 subunit beta (psbF), partial CSB-YP652396GGV
CSB-EP652396GGV
CSB-BP652396GGV
CSB-MP652396GGV
CSB-EP652396GGV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glycine max ATP synthase subunit alpha, chloroplastic (atpA), partial CSB-YP652397GGV
CSB-EP652397GGV
CSB-BP652397GGV
CSB-MP652397GGV
CSB-EP652397GGV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glycine max Photosystem II reaction center protein Z (psbZ), partial CSB-YP652398GGV1
CSB-EP652398GGV1
CSB-BP652398GGV1
CSB-MP652398GGV1
CSB-EP652398GGV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Ral GTPase-activating protein subunit alpha-2 (RALGAPA2), partial CSB-YP652399HU
CSB-EP652399HU
CSB-BP652399HU
CSB-MP652399HU
CSB-EP652399HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Glossina morsitans morsitans Chitinase-like protein Idgf1 (Idgf1) CSB-YP652400GGM
CSB-EP652400GGM
CSB-BP652400GGM
CSB-MP652400GGM
CSB-EP652400GGM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pan troglodytes Follitropin subunit beta (FSHB) CSB-YP652401EQV
CSB-EP652401EQV
CSB-BP652401EQV
CSB-MP652401EQV
CSB-EP652401EQV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rat Fibronectin type III domain-containing protein 1 (Fndc1), partial CSB-YP652402RA
CSB-EP652402RA
CSB-BP652402RA
CSB-MP652402RA
CSB-EP652402RA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>